Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. O'Connor OA, et al. J Clin Oncol. 2005 Feb 1;23(4):676-84. doi: 10.1200/JCO.2005.02.050. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613699 Clinical Trial.
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, Noy A, Portlock CS, Straus DJ, Yahalom J, Nimer SD, Moskowitz CH. Hamlin PA, et al. Among authors: portlock cs. Blood. 2003 Sep 15;102(6):1989-96. doi: 10.1182/blood-2002-12-3837. Epub 2003 Apr 3. Blood. 2003. PMID: 12676776 Free article. Clinical Trial.
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
Hamlin PA, Portlock CS, Straus DJ, Noy A, Singer A, Horwitz SM, Oconnor OA, Yahalom J, Zelenetz AD, Moskowitz CH. Hamlin PA, et al. Among authors: portlock cs. Br J Haematol. 2005 Sep;130(5):691-9. doi: 10.1111/j.1365-2141.2005.05661.x. Br J Haematol. 2005. PMID: 16115124 Free article.
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD. Moskowitz CH, et al. Among authors: portlock cs. J Clin Oncol. 2010 Apr 10;28(11):1896-903. doi: 10.1200/JCO.2009.26.5942. Epub 2010 Mar 8. J Clin Oncol. 2010. PMID: 20212248 Free PMC article.
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.
Moskowitz CH, Nimer SD, Glassman JR, Portlock CS, Yahalom J, Straus DJ, O'Brien JP, Elkin N, Bertino JR, Zelenetz AD. Moskowitz CH, et al. Among authors: portlock cs. Bone Marrow Transplant. 1999 Mar;23(6):561-7. doi: 10.1038/sj.bmt.1701624. Bone Marrow Transplant. 1999. PMID: 10217186
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD. Moskowitz CH, et al. Among authors: portlock cs. J Clin Oncol. 1999 Dec;17(12):3776-85. doi: 10.1200/JCO.1999.17.12.3776. J Clin Oncol. 1999. PMID: 10577849 Clinical Trial.
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
Portlock CS, Qin J, Schaindlin P, Roistacher N, Myers J, Filippa D, Louie D, Zelenetz AD, O'Brien JP, Moskowitz C, Norton L, Yahalom J, Straus DJ, Bertino JR. Portlock CS, et al. Ann Oncol. 2004 Oct;15(10):1495-503. doi: 10.1093/annonc/mdh390. Ann Oncol. 2004. PMID: 15367410 Free article. Clinical Trial.
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.
Moskowitz CH, Hamlin PA, Gabrilove J, Bertino JR, Portlock CS, Straus DJ, Gencarelli AN, Nimer SD, Zelenetz AD. Moskowitz CH, et al. Among authors: portlock cs. Ann Oncol. 2007 Nov;18(11):1842-50. doi: 10.1093/annonc/mdm341. Epub 2007 Sep 14. Ann Oncol. 2007. PMID: 17872903 Free article. Clinical Trial.
152 results